En español

Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders

ADHD in Adolescent Substance Abusers cover

The primary objectives of this study were to evaluate the efficacy of OROS-MPH (Concerta), relative to placebo, in treating ADHD and decreasing substance use in adolescents with ADHD and a substance use disorder. The study involved 303 participants, recruited from 11 community treatment sites.

CTN Protocol ID: 
Enrollment Status: 
ClinicalTrials.gov ID: 
Primary Outcomes Article: 

Riggs, P., et al. (2011).  Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.  Journal of the American Academy of Child & Adolescent Psychiatry 50(9):903-14.

Principal Investigator(s)
Paula Riggs, M.D.
University of Colorado School of Medicine

Theresa Winhusen, Ph.D.
Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division
University of Cincinnati
Addiction Sciences Division
3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006

Available Brochures

Get this Publication

    SAMHSA Treatment Locator

    Blending Initiative

    blending logo

    Formed with SAMHSA to reduce the gap between research results and treatment.